We would love to hear your thoughts about our site and services, please take our survey here.
Forgive me for not having confidence in the company, of course they have a clear plan.
I should be more trusting of the directors when considering the following:
SNG not used in trials since Nov 2021.
CEO not providing updates.
Delayed new trials from RNS in 2022.
MCAP from £230M to 10M.
Of course, the directors have got a clear plan!
Jint - I appreciate your clear intent for positive news.
Authorisation? We are at least 3-4 years away from this IF we get some luck on along the way.
New phase 2 trials discussed in 2022 haven't even started which will involve around 100 patients. Who is approving the drug at that stage? This company appears to be no rush to obtain authorisation.
Sadly, this company remains research company, no commercial activity ever in their 22+ year history.
I don't think I can make any profit from this share save for buying additional shares during the 4-5p range which will assist my recovery IF we get some good news.
If I can recover 30-40% of my 'investment' then I will be happy with the outcome and move on. I won't be getting involved in the stock market again.
Macosta? Please, its Mr Costs.
Most are happy to wait until end of H1? Seriously?
Do you really think our CEO will start trials within H1? Read the Sept RNS again, trials to start by end of H1 2024 SUBJECT TO...
Marsden has again provided a politicians update that when we arrive at end of H1, he can blame something external whilst his salary keeps on being paid.
'What's another month or two' Ask Marsden and he will tell you £25-50K in salary.
Scaermongering? The share price from c. £2 all the way down c. 4p did it for me.
So its agreed the article doesn't mention SNG001 or Synairgen directly?
More pin the tail on the donkey.
Brand - please copy and paste part(s) of the article which mentions SNG001 or Synairgen directly.
Not really a great find is it. No mention of SNG001 or Synairgen.
Our co founder is mentioned who also happens to have many interests outside of Synairgen. So What?
All this flirting could be sorted with an update from the company themselves.
Come the end of April, our CEO will have taken £100k in salary in 2024 thus far and has not addressed his shareholders.
Since the last patient was dosed with SNG001 in Nov 21, our CEO has taken c. £750k in salary.
We still have no clear path to recovery. The salaries continue to be taken and the silence continues.
NICE ONE DICKY
What's positive?
Our CEO stated in an RNS of May 2022 the company was focusing on new trials.
Update then reported to advise trials would start by end of 2023.
Further update to advise trials would start by end of H1 2024.
Since then no update directly to shareholders.
Can someone explain the positives? Am I missing a company update?